Who are kava (Piper methysticum)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Passiflora incarnata, chamomile tea.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/kava-piper-methysticum.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

kava (Piper methysticum) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

kava (Piper methysticum) (kava (Piper methysticum)) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Herbal anxiolytic. Area: Psychiatry/Neurology.

marketed Herbal anxiolytic Psychiatry/Neurology Small molecule Live · refreshed every 30 min

Target snapshot

kava (Piper methysticum) (kava (Piper methysticum)) — National Institutes of Health Clinical Center (CC). Kava contains kavalactones that modulate neurotransmitter activity and ion channels, producing anxiolytic and sedative effects.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
kava (Piper methysticum) TARGET	kava (Piper methysticum)	National Institutes of Health Clinical Center (CC)	marketed	Herbal anxiolytic
Passiflora incarnata	Passiflora incarnata	Nutricion Medica S.L.	marketed	Herbal anxiolytic/sedative	GABA receptors, serotonin receptors (non-selective)
chamomile tea	chamomile tea	National Center for Complementary and Integrative Health (NCCIH)	marketed	Herbal anxiolytic/sedative	GABA receptors, benzodiazepine receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Herbal anxiolytic class)

National Institutes of Health Clinical Center (CC) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). kava (Piper methysticum) — Competitive Intelligence Brief. https://druglandscape.com/ci/kava-piper-methysticum. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab